Bijwerkingen van geneesmiddelen in de oogheelkunde


onder medeverantwoordelijkheid van de redactiecommissie

Het toedienen van geneesmiddelen in het oog kan gepaard gaan met het optreden van bijwerkingen. Deze bijwerkingen kunnen zich zowel lokaal in en om het oog voordoen, als ook systemisch. Een enkele maal is een bijwerking fataal gebleken. Dit komt vooral voor bij patiënten met bestaande cardiale of pulmonale aandoeningen. Omdat er sprake is van onderrapportage van bijwerkingen, is het werkelijke risico binnen de populatie vaak niet goed bekend (Gebu 2002; 36: 63-69).

 

 






1. Hugues FC, Jeunne C le. Systemic and local tolerability of ophthalmic drug formulations. An update. Drug Saf 1993; 8: 365-380. 
2. Rennie IG. Clinically important ocular reactions to systemic drug therapy. Drug Saf 1993; 9: 196-211.
3. Polak BC. Bijwerkingen van geneesmiddelen in de oogheelkunde. In: Stilma JS, Voorn TB (red.). Praktische Oogheelkunde, 2e ed. Houten: Bohn Stafleu Van Loghum, 1996: 317-332. 
4. Polak BC. Bijwerkingen van geneesmiddelen. In: Lith, GH van (red.). Inzicht in zien. Wegwijs in de oogheelkunde. Bergen op Zoom: Lioness Books, 1998: 93-96. 
5. Fraunfelder FT. Drug-induced ocular side effects, 4th ed. Baltimore: Williams & Wilkens, 1996.
6. Polak BC. Drugs used in ocular treatment. In: Dukes MN, Aronson JK (eds.). Meyler's side effects of drugs. Amsterdam: Elsevier, 2000. 
7. Diamond JP. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging 1997; 11: 352-360. 
8. Polak BC. Oogheelkundemiddelen. In: Wesseling H, et al. (red.). Algemene Farmacotherapie, 7e ed. Houten: Bohn Stafleu Van Loghum, 1999: 783-787.
9. Polak BC. Oogdruppels soms levensgevaarlijk. Medisch Contact 2000; 55: 248-251. 
10. Polak BC, Völker-Dieben HJ. De fatale druppel. Oogdruppels met ernstige risico's voor de volksgezondheid. Pharm Weekbl 2001; 136: 317-320. 
11. Polak BC. Wat zijn de systemische effecten van bèta-blokkeerders in oogdruppels? Apothekers Vademecum 2001; nr 7. 
12. Jones FL Jr, Ekberg NL. Exacerbation of asthma by timolol. N Engl J Med 1979; 301: 270. 
13. Kruyswijk MR, Polak BC. Contactallergie na toepassing van oogdruppels en oogzalven. Ned Tijdschr Geneeskd 1980; 124: 1449-1452. 
14. Kilp H, Heisig-Salentin B, Poss W, Thode C, Rogalla K. Acute and chronic influence of benzalkonium chloride as a preservative. Concepts Toxicol 1987; 4: 59-63. 
15. Dikland WJ, Stolz E, Joost Th van. Sensibilisatie door chlooramfenicol. Ned Tijdschr Geneeskd 1985; 129: 1978-1980. 
16. Butcher JM, Austin M, McGalliard J, Bourke RD. Bilateral cataracts and glaucoma induced by long term use of steroid eye drops. BMJ 1994; 309: 43.
17. Donshik PC, Cavanaugh HD, Boruchoff SA, Dohlman CH. Posterior subcapsular cataracts induced by topical corticosteroids following keratoplasty for keratoconus. Ann Ophthalmol 1981; 13: 29-32. 
18. Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterp S. Extensive visual loss with topical facial steroids. Eye 1993; 7: 664-666. 
19. Hampson JP, Harvey JN. A systematic review of drug induced ocular reactions in diabetes. Br J Ophthalmol 2000; 84: 144-149. 
20. Black RL, Oglesby RB, Sallmann L von, Bunim JJ, Bethesda M. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 1960; 10: 150-155. 
21. Seitz B, Sorken K, LaBree LD, Garbus JJ, McDonnell PJ. Corneal sensitivity and burning sensation. Comparing topical ketorolac and diclofenac. Arch Ophthalmol 1996; 114: 921-924. 
22. Aragona P, Tripodi G, Spinella R, Lagana E, Ferreri G. The effects of the topical administration of non-steroidal anti-inflammatory drugs on corneal epithelium and corneal sensitivity in normal subjects. Eye 2000; 14: 206-210. 
23. Szerenyi K, Sorken K, Garbus JJ, Lee M, McDonnell PJ. Decrease in normal human corneal sensitivity with topical diclofenac sodium. Am J Ophthalmol 1994; 118: 312-315. 
24. Pichon P, Moreau PG. Complications cornéennes par usage de collyre indométacine. Bull Soc Opht Fr 1990; 90: 449-451. 
25. Johnson DH, Epstein DL, Allen RC, Boys-Smith J, Campbell D, Rosenquist R, et al. A one-year multicenter clinical trial of pilocarpine gel. Am J Ophthalmol 1984; 97: 723-729. 
26. Arnoult L, Bouwman ZL, Kimbrough RL, Stewart RH. Periocular changes associated with topical betaxolol. J Glaucoma 1995; 4: 263-267. 
27. Buskirk EM van. Adverse reactions from timolol administration. Ophthalmology 1980; 87: 447-450. 
28. Buckley MM, Goa KL, Clissold SP. Ocular betaxolol. A review of its pharmacological properties and therapeutic efficacy in glaucoma and ocular hypertension. Drugs 1990; 40: 75-90. 
29. Plane C. Les b -bloqueurs locaux. In: Demailly (eds.). Traitement actuel du glaucoma primitif angle ouvert. Paris: Masson, 1989: 166-187. 
30. Groot AC de, Ginkel CJ van, Bruynzeel DP, Smeenk G, Conemans JM. Contactallergie voor oogdruppels met b -blokkers. Ned Tijdschr Geneeskd 1998; 142: 1034-1036. 
31. Nino M, Suppa F, Ayala F, Balato N. Allergic contact dermatitis due to the beta-blocker befunolol in eyedrops, with cross-sensitivity to carteolol. Contact Dermatitis 2001; 44: 369. 
32. McMahon CD, Shaffer RN, Hoskins HD Jr, Hetherington J Jr. Adverse effects experienced by patients taking timolol. Am J Ophthalmol 1979; 88: 736-738. 
33. Lish AJ, et al. Effect of apraclonidine on intraocular pressure in glaucoma patients receiving maximally medications. J Glaucoma 1992; 1: 19-22. 
34. Robin A, et al. Delay of surgery by apraclonidine in patients on maximally tolerated medical therapy for glaucoma. Invest Ophthalmol Vis Sci 1994; 35: 1484. 
35. Morrison JC. Side effects of D-adrenergic agonists. J Glaucoma 1995; 4 (suppl 1): S36-S38. 
36. Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998; 12: 225-241. 
37. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997; 115: 847-852. 
38. Corwin ME, Spencer WH. Conjunctival melanin depositions. A side-effect to topical epinephrine therapy. Arch Ophthalmol 1963; 69: 317-321. 
39. Boerner CF. Total punctate keratopathy due to dipivefrin. Case report. Arch Ophthalmol 1988; 106: 171. 
40. Zhang WY, Po AL, Dua HS, Azuara-Blanco A. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2001; 85: 983-990. 
41. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye colour. Surv Ophthalmol 1997; 41: S129-S138. 
42. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124: 544-547. 
43. Wand M, Ritch R, Isbey EK Jr, Zimmerman TJ. Latanoprost and periocular skin color changes. Arch Ophthalmol 2001; 119: 614-615. 
44. Ekatomatis P. Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma. Br J Ophthalmol 2001; 85: 1008-1009. 
45. Fechtner RD, Khouri AS, Zimmerman TJ, Bullock J, Feldman R, Kulkarni P, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998; 126: 37- 41. 
46. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472-484. 
47. Taguri AH, Khan MA, Sanders R. Marginal keratitis: an uncommon form of topical dorzolamide allergy. Am J Ophthalmol 2000; 130: 120-122. 
48. Seong GJ, Lee SC, Lee JH, Chu YK, Hong YJ. Comparisons of intraocular-pressure-lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide. Ophthalmologica 2001; 215: 188-191. 
49. Strahlman E, Tipping R,Vogel R. A double-masked, randomised 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 1995; 113: 1009-1016. 
50. Henkes HE, Waubke TN. Keratitis from abuse of corneal anaesthetics. Br J Ophthalmol 1978; 62: 62-65. 
51. Newcomb RD, Ransom FG. Adverse systemic effects of ocular drug therapy. In: Bartlett, et al. (eds.) Clinical ocular pharmacology. Boston: Butterworth, 1984: 941-960. 
52. Shihab ZM. Psychotic reaction in an adult after topical cyclopentolate. Ophthalmologica 1980; 181: 228-230. 
53. Khurana AK, Ahluwalia BK, Rajan C, Vohra AK. Acute psychosis associated with topical cyclopentolate hydrochloride. Am J Ophthalmol 1988; 105: 91.
54. Birkhimer LJ, Jacobson PA, Olson J, Goyette DM. Ocular scopolamine-induced psychosis. J Fam Practice 1984; 18: 464-469. 
55. Kumar V, Packer AJ, Choi WW. Hypertension following phenylephrine 2.5% ophthalmic drops. Glaucoma 1985; 7: 131-132. 
56. Fraunfelder FT, Scafidi AF. Possible adverse effects from topical ocular 10% phenylephrine. Am J Ophthalmol 1978; 85: 447-453. 
57. Wilensky JT, Woodward HJ. Acute systemic hypertension after conjunctival instillation of phenylephrine hydrochloride. Am J Ophthalmol 1973; 76: 156-157. 
58. Fraunfelder FT, Meyer SM. Possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine. Am J Ophthalmol 1985; 99: 362-363. 
59. Abrams A, Robin AL, Pollack IP, deFaller JM, DeSantis L. Safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Arch Ophthalmol 1987; 105: 1205-1207. 
60. Rosenthal RL, Blackman A. Bone marrow hypoplasia following the use of chloramphenicol eye drops. JAMA 1955; 191: 36-37. 
61. Fraunfelder FT, Morgan RL, Yunis AA. Blood dyscrasias and topical ophthalmic chloramphenicol. Am J Ophthalmol 1993; 115: 812-813. 
62. Wiholm BE, Kelly JP, Kaufman D, Issaragrisil S, Levy M, Anderson T, et al. Relation of aplastic anaemia to use of chloramphenicol eye drops in two international case-control studies. BMJ 1998; 316: 666. 
63. Stricker BH. Bijwerkingen van geneesmiddelen. Ned Tijdschr Geneekd 1998; 142: 1572-1573. 
64. Sheehan GJ, Kutzner MR, Chin WD. Acute asthma attack due to ophthalmic indomethacin. Ann Intern Med 1989; 15: 337-338. 
65. Markman HD, Rosenberg P, Dettbarn W. Eye drops and diarrhoea: diarrhoea as the first symptom of ecothiophate iodide toxicity. N Engl J Med 1964; 271: 197-198. 
66. Ellis PP. Systemic reactions to topical therapy. Int Ophthalmol Clin 1971; 11: 1-11. 
67. Greco JJ, Kelman CD. Systemic pilocarpine toxicity in the treatment of angle-closure glaucoma. Ann Ophthalmol 1973; 5: 57-59.
68. Gerber SL, Cantor LB, Brater DC. Systemic drug interactions with topical glaucoma medications. Surv Ophthalmol 1990; 5: 205-218. 
69. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kurutsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 1986; 102: 606-611. 
70. Duncan TE. Side effects of ocular timolol. Am J Ophthalmol 1983; 95: 562-563. 
71. Chamberlain TJ. Myocardial infarction after ophthalmic betaxolol. N Engl J Med 1989; 321: 1342. 
72. Vinti H, Pesce A, Taillan B, Kreitman P, Cassuto JP, Dujardin P. Anthracycline-induced cardiomyopathy and heart transplantation. Eur J Med 1992; 1: 313. 
73. Cervantes R, Hernandez Y, Hernandez H. Pulmonary and heart rate changes associated with non selective b -blocker therapy. J Toxicol Cutaneous Ocul Toxicol 1986; 5: 185-193. 
74. Jeunne C le, Bringer L, Mondjee-Tahura Z, Munera Y, Hugues FC. Effects cardiovasculaires des collyres au timolol, au cartéolol, au métipranolol, et au bétaxolol chez le sujet âgé. Thérapie 1988; 43: 89-92. 
75. Diggory P, Cassels-Brown A, Vail A, Abbey LM, Hillman JS. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet 1995; 345: 1604-1606. 
76. Huerta C, Garcia Rodriguez LA, Moller CS, Arellano FM. The risk of obstructive airways disease in a glaucoma population. Pharmacoepidemiol Drug Saf 2001; 10: 157-163. 
77. Anonymous. Systemic adverse reactions with betaxolol eye drops. Med J Austr 1995; 162: 84. 
78. Ball S. Congestive heart failure from betaxolol. Case report. Arch Ophthalmol 1987; 105: 320. 
79. Nelson WL, Kuritsky JN. Early postmarketing surveillance of betaxolol hydrochloride, september 1985-september 1986. Am J Ophthalmol 1987; 103: 592. 
80. Schweitzer I, Maguire K, Tuckwell V. Antiglaucoma medication and clinical depression. Aust N Z J Psychiatry 2001; 35: 569-571. 
81. Berlin RJ, Lee UT, Samples JR, Rich LF, Tang-Liu DD, Sing KA, et al. Ophthalmic drops causing coma in an infant. J Pediatr 2001; 138: 441-443. 
82. Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol 2001; 119: 300-301.
83. Mitra M, Chang B, James T. Drug points. Exacerbation of angina associated with latanoprost. BMJ 2001; 323: 783. 
84. Martin XD, Danese M. Dorzolamide-induced immune thrombocytopenia: a case report and literature review. J Glaucoma 2001; 10: 133-135. 
85. Schwartzenberg GW thoe, Trope GE. Anorexia, depression and dementia induced by dorzolamide eyedrops (Trusopt). Can J Ophthalmol 1999; 34: 93-94. 
86. Carlsen J, Durcan J, Zabriskie N, Swartz M, Crandall A. Nephrolithiasis with dorzolamide. Arch Ophthalmol 1999; 117: 1087-1088. 
87. Fraunfelder FT, Meyer SM, Bagby GC Jr, Dreis MW. Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthalmol 1985; 100: 79-81. 
88. Keisu M, Wiholm BE, Ost A, Mortimer O. Acetazolamide-associated aplastic anaemia. J Intern Med 1990; 228: 627-632. 
89. Gerhards LJ, Arnhem AC van, Holman ND, Nossent GD. Fatale anafylactische reactie na inname van acetazolamide (Diamox) wegens glaucoom. Ned Tijdschr Geneeskd 2000; 144: 1228-1230. 
90. Kachi S, Hirano K, Takesue Y, Miura M. Unusual corneal deposit after the topical use of cyclosporine as eyedrops. Am J Ophthalmol 2000; 130: 667-669. 
91. Polak BC, Jong PT de. Bijwerkingen van geneesmiddelen. Contactlenzen en geneesmiddelengebruik. Ned Tijdschr Geneeskd 1984; 128: 1622-1625.    

Auteurs

  • mw prof. dr B.C.P. Polak, drs D. Bijl